Emiliana Tjitra

TL;DR: Progress in reducing the burden of disease will require improved access to reliable diagnosis and effective treatment of both blood-stage and latent parasites, and more detailed characterization of the epidemiology, morbidity, and economic impact of vivax malaria.

TL;DR: In this region with established high-grade chloroquine resistance to both Pv and Pf, Pv is associated with severe and fatal malaria particularly in young children, particularly in children under 1 y of age.

TL;DR: Clinical trials in SM of adjunctive agents to improve endothelial NO bioavailability, including l-arginine, are warranted after an observational study in Indonesia found endothelial dysfunction was associated with elevated blood lactate and measures of hemolysis and likely contributes to its pathogenesis.

TL;DR: Both dihydroartemisinin-piperaquine and artemether-lumefantrine were safe and effective for the treatment of multidrug-resistant uncomplicated malaria, however, diHydroart Artemisin in-pipersaquine provided greater post-treatment prophylaxis than did artem ether- lumefanrine, reducing P falciparum reinfections and P vivax recurrences.

TL;DR: Agents that improve endothelial NO, reduce WPB exocytosis, and/or antagonize Ang-2 may have therapeutic roles in SM and contribute to endothelial activation, sequestered parasite biomass, impaired perfusion, and poor outcome in severe falciparum malaria.